Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | NOTCH1 wild-type RB1 wild-type |
Therapy | Everolimus + Ribociclib |
Indication/Tumor Type | T-cell adult acute lymphocytic leukemia |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
NOTCH1 wild-type RB1 wild-type | T-cell adult acute lymphocytic leukemia | sensitive | Everolimus + Ribociclib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, the combination of Kisqali (ribociclib) and Afinitor (everolimus) treatment in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 resulted in decreased Rb1 phosphorylation and a greater inhibition of cell growth compared to either agent alone in culture, and prolonged survival in cell-line xenograft models (PMID: 28151717). | 28151717 |
PubMed Id | Reference Title | Details |
---|---|---|
(28151717) | Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia. | Full reference... |